ClearPoint Neuro, Inc. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
ClearPoint Neuro reported Q3 2026 revenue of $12.1M (vs. $8.9M YoY), driven by 59% growth in neurosurgery navigation/therapy to $5.4M and 68% growth in capital equipment/software to $1.7M, including contributions from the acquired IRRA flow portfolio. Biologics/drug delivery grew 11% to $4.9M. The company raised $22.0M net from at-the-market offering and ended the quarter with $46.2M cash. Full-year 2026 revenue guidance: $48.0M–$50.0M. Operating expenses grew 23% YoY to $13.4M; gross margin declined to 58% from 63% due to new Advanced Laboratories overhead and amortization. Net loss widened to $7.5M (Q3) from $5.9M YoY.
Why this rating
36% revenue growth and successful IRRA integration are encouraging, but company remains unprofitable with deteriorating margins. Relative to ~$328M market cap, $12.1M quarterly revenue (annualized ~$48M) and positive cash position mitigate but don't eliminate execution risk.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.